Galectin Therapeutics 内部人士出售了大量股票，引发了人们对生物制药未来的看法。 Galectin Therapeutics insiders sold substantial stock shares, raising questions about the biopharm's future.

Gaectin治疗公司内部人最近出售了大量股票。 Galectin Therapeutics Inc. insiders sold significant stock shares recently. CFO Jack Callickut出售了40,000股,CEO Joel Lewis出售了56,000股,内幕人Khurram Jamil出售了13,654股。 CFO Jack Callicutt sold 40,000 shares, CEO Joel Lewis sold 56,000 shares, and insider Khurram Jamil sold 13,654 shares. 该公司是一家生物制药公司,在NASH肝硬化、肝纤维化和其他疾病的临床试验中有一个主要产品候选者Belapetin。 The company is a biopharmaceutical firm with a lead product candidate, belapectin, in clinical trials for NASH cirrhosis, liver fibrosis, and other diseases. Gaectin治疗药物的市场上限为7 218万美元。 Galectin Therapeutics has a market cap of $72.18 million.